SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013 Plan Quarter Payment Customer	Dec. 31, 2012 Payment	Dec. 31, 2011
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	$ 5,004,418	$ 5,082,360
Number of customers	2
Royalty revenue	11,767,758	9,155,654	6,314,959
Deferred revenue	100,000	100,000
Royalty / Mark-up on Cost of Goods Sold / Earn-Out Revenue [Abstract]
Number of quarters after which revenue is recognized	1
Number of days after calendar year, after which payments and report are received	90 days
Number of years for which bad debt expense not recorded	3 years
Allowance for doubtful accounts	30,095	30,095
Reimbursable Third Party Development Costs [Abstract]
Accrued patent costs	60,000
Royalty Buy-Down [Abstract]
Initial payment for royalty buy down	600,000	1,500,000	0
Number of additional cash payments for royalty buy-down		5
Number of cash payments made for royalty obligation	1
Deferred royalty buy-down	3,350,000	2,750,000
Deferred costs, amortization period	5 years
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Number of stock based compensation plans in effect	2
Stock-based compensation expense	111,636	228,485	517,367
Stock options granted (in shares)	30,000	15,000	0
Patent cost, net [Abstract]
Patents, net	215,999	280,322	190,416
Amortization expense for patents	64,323	64,190	50,685
Estimated aggregate amortization expense [Abstract]
2014	53,000
2015	25,000
2016	20,000
2017	20,000
2018	20,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment (in years)	5 years
Intangible assets with definite lives useful life (in years)	1 year
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment (in years)	10 years
Intangible assets with definite lives useful life (in years)	13 years
Non-Employee Consultants [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	79,049	109,479	0
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	92,249	171,217	96,849
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	19,387	57,268	420,518
DFB Biotech Inc. [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	3,500,000
Royalty revenue	3,500,000
DFB Biotech Inc. [Member] | Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	70.00%
DFB Biotech Inc. [Member] | Licensing, Consulting And Royalty Revenue [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	30.00%
Auxilium [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	1,500,000
Royalty revenue	8,200,000
Deferred revenue	$ 200,000
Auxilium [Member] | Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	30.00%
Auxilium [Member] | Licensing, Consulting And Royalty Revenue [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	70.00%